Rigel Pharma (RIGL) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Rigel Announces First Quarter 2015 Financial Results
May 7, 2015 4:06 PM EDTSOUTH SAN FRANCISCO, Calif., May 7, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2015.
For the first quarter of 2015, Rigel reported a net loss of $18.2 million, or $0.21 per share, compared to a net loss of $22.3 million, or $0.25 per share, in the first quarter of 2014. Weighted average shares outstanding for the first quarters of 2015 and 2014 were 88.0 million and 87.5 million, respectively.
Contract revenues from collaborations of $2.2 million in the first quarter of 2015 were comprised of $2.1 million from the amortization of the $30.0 million upfront... More
